Compare iShares MSCI Indonesia ETF (EIDO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Zoetis Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares MSCI Indonesia ETF pays none, and iShares MSCI Indonesia ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | ZTS | |
|---|---|---|
52-Week High | $19.22 | $156.76 |
52-Week Low | $10.80 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.69, down 0.47% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces resistance near $13 and support at $12. Recent news highlights Indonesia's economic initiatives and central bank rate hikes, but the ETF's heavy financials weighting and weak price action persist. Key financial ratios are not provided in the current dataset.
The outlook remains cautious due to technical downtrend and external pressures on Asian equities. Opportunities exist if Indonesia's AI integration and reforestation plans boost economic growth, but risks include currency volatility and limited earnings growth. Investor sentiment is neutral to bearish amid capital outflows from regional markets.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
